EyePoint price target lowered to $33 from $38 at Baird
In This Article:
Baird lowered the firm’s price target on EyePoint (EYPT) to $33 from $38 and keeps an Outperform rating on the shares. The firm said they reported 3Q24 results and recapped recent progress, including recently reported, unexpectedly positive, interim data in the Phase 2 VERONA study in DME, and the dosing of the first patient in the pivotal LUGANO study in wet AMD.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on EYPT:
Terms and Privacy Policy